Trial Radar
Sign in

Study record

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT07436741

RecruitingPhase 3

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions: Pancreatic Cancer, Adult

Interventions: surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel

Countries: China

To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

1 events · 1 snapshots

1 recorded events1 registry snapshotsTracked since Jul 13, 2026Official CT.gov history
  1. Jul 13, 2026
    New TrialNotable

    Tianjin Medical University Cancer Institute and Hospital started Phase 3 Pancreatic Cancer, Adult trial

    Registry state after update: Recruiting · Phase 3 · 1 countries

← Back to dashboard